|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global Cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yuan N, Meng M, Liu C, Feng L, Hou L, Ning
Q, Xin G, Pei L, Gu S, Li X and Zhao X: Clinical characteristics
and prognostic analysis of triple-negative breast cancer patients.
Mol Clin Oncol. 2:245–251. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750̄–2767.
2011. View
Article : Google Scholar
|
|
5
|
Gerratana L, Fanotto V, Bonotto M,
Bolzonello S, Minisini AM, Fasola G and Puglisi F: Pattern of
metastasis and outcome in patients with breast cancer. Clin Exp
Metastasis. 32:125–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsai CH, Chiu JH, Yang CW, Wang JY, Tsai
YF, Tseng LM, Chen WS and Shyr YM: Molecular characteristics of
recurrent triple-negative breast cancer. Mol Med Rep. 12:7326–7334.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
M Braden A, V Stankowski R, M Engel J and
A Onitilo A: Breast cancer biomarkers: Risk assessment, diagnosis,
prognosis, prediction of treatment efficacy and toxicity, and
recurrence. Curr Pharm Des. 20:4879–4898. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang C, Hou C, Zhang H, Wang D, Ma Y,
Zhang Y, Xu X, Bi Z and Geng S: miR-126 functions as a tumor
suppressor in osteosarcoma by targeting Sox2. Int J Mol Sci.
15:423–437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Najafi Z, Sharifi M and Javadi G:
Degradation of miR-21 induces apoptosis and inhibits cell
proliferation in human hepatocellular carcinoma. Cancer Gene Ther.
22:530–535. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sandhu R, Rivenbark AG, Mackler RM, Livasy
CA and Coleman WB: Dysregulation of microRNA expression drives
aberrant DNA hypermethylation in basal-like breast cancer. Int J
Oncol. 44:563–572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu X, Li H, Long L, Hui L, Chen H, Wang
X, Shen H and Xu W: miR-126 enhances the sensitivity of non-small
cell lung cancer cells to anticancer agents by targeting vascular
endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai).
44:519–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu Q, Liu SL, Wang H, Shi G, Yang P and
Chen X: miR-126 suppresses the proliferation of cervical cancer
cells and alters cell sensitivity to the chemotherapeutic drug
bleomycin. Asian Pac J Cancer Prev. 14:6569–6572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Akao Y, Noguchi S, Iio A, Kojima K, Takagi
T and Naoe T: Dysregulation of microRNA-34a expression causes
drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer
Lett. 300:197–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuhnert F, Mancuso MR, Hampton J,
Stankunas K, Asano T, Chen C and Kuo CJ: Attribution of vascular
phenotypes of the murine Egfl7 locus to the microRNA miR-126.
Development. 135:3989–3993. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu W, Zhao ZY, Shi L and Yuan WD: Tissue
microRNA-126 expression level predicts outcome in human
osteosarcoma. Diagn Pathol. 10:1162015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hansen TF, Nielsen BS, Jakobsen A and
Sørensen FB: Intra-tumoural vessel area estimated by expression of
epidermal growth factor-like domain 7 and microRNA-126 in primary
tumours and metastases of patients with colorectal cancer: A
descriptive study. J Transl Med. 13:102015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fujii T, Shimada K, Tatsumi Y, Fujimoto K
and Konishi N: Syndecan-1 responsive microRNA-126 and 149 regulate
cell proliferation in prostate cancer. Biochem Biophys Res Commun.
456:183–189. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu LY, Wang W, Zhao LY, Guo B, Yang J,
Zhao XG, Hou N, Ni L, Wang AY, Song TS, et al: MiR-126 inhibits
growth of SGC-7901 cells by synergistically targeting the oncogenes
PI3KR2 and Crk, and the tumor suppressor PLK2. Int J Oncol.
45:1257–1265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kirschmann DA, Seftor EA, Hardy KM, Seftor
RE and Hendrix MJ: Molecular pathways: Vasculogenic mimicry in
tumor cells: Diagnostic and therapeutic implications. Clin Cancer
Res. 18:2726–2732. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meister J and Schmidt MHH: miR-126 and
miR-126*: New players in cancer. ScientificWorldJournal.
10:2090–2100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu T, Sun B, Zhao X, Li Y, Gu Q, Dong X
and Liu F: OCT4 expression and vasculogenic mimicry formation
positively correlate with poor prognosis in human breast cancer.
Int J Mol Sci. 15:19634–19649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu T, Sun B, Zhao X, Gu Q, Dong X, Yao Z,
Zhao N, Chi J, Liu N, Sun R and Ma Y: HER2/neu expression
correlates with vasculogenic mimicry in invasive breast carcinoma.
J Cell Mol Med. 17:116–122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shirakawa K, Kobayashi H, Sobajima J,
Hashimoto D, Shimizu A and Wakasugi H: Inflammatory breast cancer:
Vasculogenic mimicry and its hemodynamics of an inflammatory breast
cancer xenograft model. Breast Cancer Res. 5:136–139. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dulin NO, Pratt P, Tiruppathi C, Niu J,
Voyno-Yasenetskaya T and Dunn MJ: Regulator of G protein signaling
RGS3T is localized to the nucleus and induces apoptosis. J Biol
Chem. 275:21317–21323. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eusemann TN, Willmroth F, Fiebich B, Biber
K and van Calker D: Adenosine receptors differentially regulate the
expression of regulators of G-protein signalling (RGS) 2, 3 and 4
in astrocyte-like cells. PLoS One. 10:e01349342015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sethakorn N and Dulin NO: RGS expression
in cancer: Oncomining the cancer microarray data. J Recept Signal
Transduct Res. 33:166–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tatenhorst L, Senner V, Püttmann S and
Paulus W: Regulators of G-protein signaling 3 and 4 (RGS3, RGS4)
are associated with glioma cell motility. J Neuropathol Exp Neurol.
63:210–222. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J,
Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour
suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Chen X, Li P, Su L, Yu B, Cai Q,
Li J, Yu Y, Liu B and Zhu Z: CRKL promotes cell proliferation in
gastric cancer and is negatively regulated by miR-126. Chem Biol
Interact. 206:230–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Zhou Y, Fei X, Chen X and Zhu Z:
Regulator of G-protein signaling 3 targeted by miR-126 correlates
with poor prognosis in gastric cancer patients. Anticancer Drugs.
28:161–169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Piasecka D, Braun M, Kordek R, Sadej R and
Romanska H: MicroRNAs in regulation of triple-negative breast
cancer progression. J Cancer Res Clin Oncol. 144:1401–1411. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang L, Xu Y, Jin X, Wang Z, Wu Y, Zhao
D, Chen G, Li D, Wang X, Cao H, et al: A circulating miRNA
signature as a diagnostic biomarker for non-invasive early
detection of breast cancer. Breast Cancer Res Treat. 154:423–434.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang B, Li J, Sun M, Sun L and Zhang X:
miRNA expression in breast cancer varies with lymph node metastasis
and other clinicopathologic features. IUBMB Life. 66:371–377. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gomes BC, Martins M, Lopes P, Morujão I,
Oliveira M, Araújo A, Rueff J and Rodrigues AS: Prognostic value of
microRNA-203a expression in breast cancer. Oncol Rep. 36:1748–1756.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Zhang Z and Wang J: MicroRNA-384
inhibits the progression of breast cancer by targeting ACVR1. Oncol
Rep. 39:2563–2574. 2018.PubMed/NCBI
|
|
40
|
Zhang HD, Jiang LH, Hou JC, Zhou SY, Zhong
SL, Zhu LP, Wang DD, Yang SJ, He YJ, Mao CF, et al: Circular RNA
has_circ_0072995 promotes breast cancer cell migration and invasion
through sponge for miR-30c-2-3p. Epigenomics. 10:1229–1242. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Paszek S, Gabło N, Barnaś E, Szybka M,
Morawiec J, Kołacińska A and Zawlik I: Dysregulation of microRNAs
in triple-negative breast cancer. Ginekol Pol. 88:530–536. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Otsubo T, Akiyama Y, Hashimoto Y, Shimada
S, Goto K and Yuasa Y: MicroRNA-126 inhibits SOX2 expression and
contributes to gastric carcinogenesis. PLoS One. 6:e166172011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Guo C, Sah JF, Beard L, Willson JK,
Markowitz SD and Guda K: The noncoding RNA, miR-126, suppresses the
growth of neoplastic cells by targeting phosphatidylinositol
3-kinase signaling and is frequently lost in colon cancers. Genes
Chromosomes Cancer. 47:939–946. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang J, Du YY, Lin YF, Chen YT, Yang L,
Wang HJ and Ma D: The cell growth suppressor, miR-126, targets
IRS-1. Biochem Biophys Res Commun. 377:136–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chang YY, Kuo WH, Hung JH, Lee CY, Lee YH,
Chang YC, Lin WC, Shen CY, Huang CS, Hseih FJ, et al: Deregulated
microRNAs in triple-negative breast cancer revealed by deep
sequencing. Mol Cancer. 14:362015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu Y, Cai Q, Bao PP, Su Y, Cai H, Wu J,
Ye F, Guo X, Zheng W, Zheng Y and Shu XO: Tumor tissue microRNA
expression in association with triple-negative breast cancer
outcomes. Breast Cancer Res Treat. 152:183–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Turashvili G, Lightbody ED, Tyryshkin K,
SenGupta SK, Elliott BE, Madarnas Y, Ghaffari A, Day A and Nicol
CJB: Novel prognostic and predictive microRNA targets for
triple-negative breast cancer. FASEB J. 29:fj201800120R2018.
|
|
48
|
Baldassari F, Zerbinati C, Galasso M,
Corrà F, Minotti L, Agnoletto C, Previati M, Croce CM and Volinia
S: Screen for microRNA and drug interactions in breast cancer cell
lines points to miR-126 as a modulator of CDK4/6 and PIK3CA
inhibitors. Front Genet. 9:1742018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW,
Che N, Wang XH, Du J, Liu YX and Sun BC: Expression and functional
significance of Twist1 in hepatocellular carcinoma: Its role in
vasculogenic mimicry. Hepatology. 51:545–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu R, Yang K, Meng C, Zhang Z and Xu Y:
Vasculogenic mimicry is a marker of poor prognosis in prostate
cancer. Cancer Biol Ther. 13:527–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang JY, Sun T, Zhao XL, Zhang SW, Zhang
DF, Gu Q, Wang XH, Zhao N, Qie S and Sun BC: Functional
significance of VEGF-a in human ovarian carcinoma: Role in
vasculogenic mimicry. Cancer Biol Ther. 7:758–766. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li Y, Sun B, Zhao X, Zhang D, Wang X, Zhu
D, Yang Z, Qiu Z and Ban X: Subpopulations of uPAR+ contribute to
vasculogenic mimicry and metastasis in large cell lung cancer. Exp
Mol Pathol. 98:136–144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q,
Dong X, Li J, Liu F, Jia X, et al: Twist1 expression induced by
sunitinib accelerates tumor cell vasculogenic mimicry by increasing
the population of CD133+ cells in triple-negative breast cancer.
Mol Cancer. 13:2072014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wagenblast E, Soto M, Gutiérrez-Ángel S,
Hartl CA, Gable AL, Maceli AR, Erard N, Williams AM, Kim SY,
Dickopf S, et al: A model of breast cancer heterogeneity reveals
vascular mimicry as a driver of metastasis. Nature. 520:358–362.
2015. View Article : Google Scholar : PubMed/NCBI
|
